C the Signs (https://cthesigns.com) is an artificial intelligence-powered cancer prediction system designed to help healthcare providers identify patients at risk of cancer at the earliest, most treatable stage. The platform enables clinicians, individuals, and health systems to spot those at risk while maximizing time, options, and outcomes for patients.
C the Signs works across the entire patient journey, providing real-time clinical support seamlessly integrated into medical consultations. Built by doctors for doctors, it enhances decision-making without adding complexity to workflows. The system leverages AI to identify rare, complex, or vague cancer presentations, recommends personalized investigations or referrals based on national and local guidelines, and draws on a database of over 1,000 validated signs, symptoms, and risk factors. Notably, it allows patients to assess their own risk and book diagnostic tests directly, bypassing the need to see a doctor first in some cases. The platform also proactively scans electronic health records across populations to identify at-risk individuals before clinical suspicion arises, enabling earlier intervention and transforming population screening efforts.
How Was C the Signs Started?
C the Signs was founded by Dr Bea Bakshi, MD (Co-founder & CEO), and Dr Miles Payling, MD (Co-founder and Chief Scientific Officer), both medical doctors with a mission to improve early cancer detection. The company’s leadership includes a multidisciplinary team of clinicians, technologists, and data scientists, supported by advisors with experience in healthcare innovation, AI, and cancer policy.
Who Uses C the Signs?
C the Signs is used by healthcare providers, clinicians, health systems, and patients aiming to improve the early detection of cancer. The platform is designed for use in clinical settings—such as primary care practices, hospitals, and health networks—as well as for individuals who want to proactively assess their cancer risk.
What Makes C the Signs Different?
- Real-time clinical decision support integrated into consultations
- AI-powered identification of rare or complex cancer presentations
- Personalized investigation and referral recommendations based on local and national guidelines
- Over 1,000 validated signs, symptoms, and risk factors included in its algorithms
- Patient-facing risk assessment and direct booking for diagnostic tests
- Population-level screening by scanning electronic health records for early signals of cancer
Who Leads C the Signs?
The founding team, Dr Bea Bakshi and Dr Miles Payling, bring direct clinical experience to the company’s mission. The broader leadership includes clinical, technical, product, and data experts such as Ken Wu (Chief Technology Officer), John Woolley (Clinical Lead), and Matt Wolfe (Director of Software Engineering). Notable advisors include Dr Todd Rothenhaus (CEO, Cohealo), Antonio Gulli (Director of Engineering, Google), Michael Luck (Professor of AI, King's College London), and Greg Simon (former Executive Director of the White House Cancer Moonshot Task Force).
Use PromptLoop to Uncover Company Data
Looking for more company insights like this? PromptLoop helps you go deeper, providing unique data points and analysis on companies like C the Signs and many others. Automate your research and find the information that matters most. Discover how PromptLoop can accelerate your market intelligence. Get A Free Demo to learn more.